Study of Paclitaxel Infusion in Children with Tumors
Author Information
Author(s): Doz F, Gentet J C, Pein F, Frappaz D, Chastagner P, Moretti S, Vassal G, Arditti J, Tellingen O Van, Iliadis A, Catalin J
Primary Institution: Departement d'Oncologie Pédiatrique, Institut Curie
Hypothesis
Can a 3-hour infusion of paclitaxel be safely administered to children with refractory solid tumors without increasing toxicity?
Conclusion
The study found that while no dose-limiting haematological toxicity was observed, the 3-hour paclitaxel infusion schedule is not recommended due to acute neurological toxicity.
Supporting Evidence
- 20 courses were studied in 17 patients.
- 4 dosage levels of paclitaxel were investigated.
- No dose-limiting haematological toxicity was observed.
- Severe acute neurological and allergic toxicity was encountered.
- One treatment-related death occurred at the highest dosage.
Takeaway
Doctors tested a new way to give a cancer medicine to kids, but it caused some serious side effects, so they decided it wasn't safe.
Methodology
Paclitaxel was administered as a 3-hour infusion after premedication, and pharmacokinetic analysis was performed during the first course.
Limitations
The study encountered severe acute neurological and allergic toxicity, leading to a treatment-related death.
Participant Demographics
Patients aged 6 months to 20 years with refractory malignant solid tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website